| Dr Mark Charles Kory, MD | |
|
16216 Baxter Rd, Suite 200, Chesterfield, MO 63017-4770 | |
| (636) 532-1000 | |
| (636) 532-1605 |
| Full Name | Dr Mark Charles Kory |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 38 Years |
| Location | 16216 Baxter Rd, Chesterfield, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326034489 | NPI | - | NPPES |
| Entity Name | Mark C Kory Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568582369 PECOS PAC ID: 2860564200 Enrollment ID: O20080701000028 |
News Archive
Mast cells are immune cells known mostly for their unwanted effects: they cause the wheezing of asthma, the itching of eczema, the sneezing and runny nose of hay fever and, in extreme cases, the life-threatening shock of anaphylaxis.
A new study from American Cancer Society researchers finds a surprising number of Americans believe scientifically unsubstantiated claims concerning cancer, and that population segments suffering the greatest burden of cancer are the most likely to be misinformed.
A review of more than 100 studies found overweight girls tend to reach puberty earlier than their peers do.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Charles Kory, MD 1456 Haarman Oak Dr, Chesterfield, MO 63005-4286 Ph: (636) 530-7546 | Dr Mark Charles Kory, MD 16216 Baxter Rd, Suite 200, Chesterfield, MO 63017-4770 Ph: (636) 532-1000 |
News Archive
Mast cells are immune cells known mostly for their unwanted effects: they cause the wheezing of asthma, the itching of eczema, the sneezing and runny nose of hay fever and, in extreme cases, the life-threatening shock of anaphylaxis.
A new study from American Cancer Society researchers finds a surprising number of Americans believe scientifically unsubstantiated claims concerning cancer, and that population segments suffering the greatest burden of cancer are the most likely to be misinformed.
A review of more than 100 studies found overweight girls tend to reach puberty earlier than their peers do.
MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.
› Verified 6 days ago
Dr. George J. Hruza, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1001 Chesterfield Pkwy E, Ste 101, Chesterfield, MO 63017 Phone: 314-878-3839 Fax: 314-878-6575 | |
Wayne Alan Breer, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1001 Chesterfield Pkwy E, Suite 201, Chesterfield, MO 63017 Phone: 636-532-2422 Fax: 636-532-2425 | |
Regina Cruz Bowers, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 224 S Woods Mill Rd, 570-s, Chesterfield, MO 63017 Phone: 314-878-2556 Fax: 314-275-7442 | |
Dr. Pooja Manjula Swamy Dorward, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1001 Chesterfield Pkwy E, Suite 201, Chesterfield, MO 63017 Phone: 636-532-2422 Fax: 636-532-2425 | |
Daniel Scott Ring, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1001 Chesterfield Pkwy E, Suite 201, Chesterfield, MO 63017 Phone: 636-532-2422 Fax: 636-532-2425 | |
Dr. Susan Akers Blattel, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1001 Chesterfield Pkwy E, Suite 201, Chesterfield, MO 63017 Phone: 636-532-2422 Fax: 636-532-2425 |